de Haan Marlon J A, Jacobs Marleen E, de Graaf Annemarie M A, van Scheppingen Roan H, Derks Rico J E, de Vries Dorottya K, Kers Jesper, Alwayn Ian P J, van Kooten Cees, Sánchez-López Elena, Giera Martin, Engelse Marten A, Rabelink Ton J
Department of Internal Medicine (Nephrology) & Einthoven Laboratory of Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands.
The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Leiden University Medical Center, Leiden, The Netherlands.
Nat Commun. 2025 Jul 1;16(1):5420. doi: 10.1038/s41467-025-61058-9.
Ex vivo normothermic machine perfusion has been proposed to protect deceased donor kidneys. However, its benefits remain ambiguous. We postulate that the use of red blood cells (RBCs) and associated secondary hemolysis may in fact cause renal injury, offsetting potential advantages. During 48-hour normothermic perfusion of seven human donor kidneys, we observed progressive hemolysis, leading to iron accumulation in perfusate and tissue. Untargeted lipidomic profiling revealed significant increases in oxidized phospholipid species in perfused kidneys, pointing towards iron-dependent cell death known as ferroptosis. Next, in twelve additional perfusions, we assessed strategies to mitigate hemolysis-driven injury. Dialysis-based free hemoglobin removal reduced lipid peroxidation, but a ferroptosis gene signature persisted. In contrast, cell-free perfusion at subnormothermia negated iron accumulation, the ferroptosis gene signature, phospholipid peroxidation, and acute kidney injury. Our findings highlight the pathological role of hemolysis and iron on the kidney, urging restraint in the clinical application of RBC-based kidney perfusion.
已提出采用体外常温机器灌注来保护已故供体肾脏。然而,其益处仍不明确。我们推测,红细胞(RBC)的使用及相关的继发性溶血实际上可能导致肾损伤,抵消潜在优势。在对七个供体人肾进行48小时常温灌注期间,我们观察到进行性溶血,导致灌流液和组织中铁蓄积。非靶向脂质组学分析显示,灌注肾脏中氧化磷脂种类显著增加,表明存在铁依赖性细胞死亡,即铁死亡。接下来,在另外十二次灌注中,我们评估了减轻溶血驱动损伤的策略。基于透析的游离血红蛋白清除减少了脂质过氧化,但铁死亡基因特征仍然存在。相比之下,亚常温下的无细胞灌注消除了铁蓄积、铁死亡基因特征、磷脂过氧化和急性肾损伤。我们的研究结果突出了溶血和铁对肾脏的病理作用,促使在基于红细胞的肾脏灌注临床应用中保持谨慎。